Role of galectin-3 in bone cell differentiation, bone pathophysiology and vascular osteogenesis by Iacobini, Carla et al.
 International Journal of 
Molecular Sciences
Review
Role of Galectin-3 in Bone Cell Differentiation,
Bone Pathophysiology and Vascular Osteogenesis
Carla Iacobini ID , Claudia Blasetti Fantauzzi, Giuseppe Pugliese * ID and Stefano Menini ID
Department of Clinical and Molecular Medicine, La Sapienza University, 00185 Rome, Italy;
carla.iacobini@uniroma1.it (C.I.); claudia.blasettifantauzzi@uniroma1.it (C.B.F.);
stefano.menini@uniroma1.it (S.M.)
* Correspondence: giuseppe.pugliese@uniroma1.it; Tel.: +39-063-377-5440; Fax: +39-063-377-6327
Received: 31 October 2017; Accepted: 19 November 2017; Published: 21 November 2017
Abstract: Galectin-3 is expressed in various tissues, including the bone, where it is considered
a marker of chondrogenic and osteogenic cell lineages. Galectin-3 protein was found to be
increased in the differentiated chondrocytes of the metaphyseal plate cartilage, where it favors
chondrocyte survival and cartilage matrix mineralization. It was also shown to be highly expressed
in differentiating osteoblasts and osteoclasts, in concomitance with expression of osteogenic markers
and Runt-related transcription factor 2 and with the appearance of a mature phenotype. Galectin-3
is expressed also by osteocytes, though its function in these cells has not been fully elucidated.
The effects of galectin-3 on bone cells were also investigated in galectin-3 null mice, further supporting
its role in all stages of bone biology, from development to remodeling. Galectin-3 was also shown to
act as a receptor for advanced glycation endproducts, which have been implicated in age-dependent
and diabetes-associated bone fragility. Moreover, its regulatory role in inflammatory bone and joint
disorders entitles galectin-3 as a possible therapeutic target. Finally, galectin-3 capacity to commit
mesenchymal stem cells to the osteoblastic lineage and to favor transdifferentiation of vascular
smooth muscle cells into an osteoblast-like phenotype open a new area of interest in bone and
vascular pathologies.
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1. Introduction
Galectin-3 is a 29- to 35-kDa protein belonging to the family of the β-galactoside binding
animal lectins and is constitutively expressed in various tissues, including the bone [1]. It is the
only chimera-type galectin in vertebrates and comprises one conserved carbohydrate recognition
domain linked to a non-lectin domain through a collagen-like linker region [2]. This lectin has been
recognized over the past two decades as being involved in many physiological and pathological
processes [2,3]. In quiescent cells, galectin-3 shows prominent cytoplasmic localization, whereas it
is found predominantly in the nucleus of replicating cells [3]. Galectin-3 is also secreted into
the extracellular space through a non-classical secretory pathway [4]. Here, it interacts with the
β-galactoside residues of several glycoproteins, thus forming higher order supramolecular structures
resulting in galectin-ligand lattices on the cell surface [5]. These lattices have been shown to play a major
role in the regulation of receptor clustering, endocytosis and signaling, thereby controlling important
cell functions such as cell transdifferentiation, migration, and fibrogenesis [5,6]. As a component of the
cell surface lattice, galectin-3 also regulates the biogenesis of a subpopulation of clathrin-independent
carriers involved in the endocytosis of specific cargo proteins, which could represent one of the main
mechanisms behind its functions [7].
Intracellular galectin-3 has been implicated in several basic cellular processes related to control of
cell differentiation, growth, and apoptosis, as well as in specific cell biosynthetic activities. Galectin-3
Int. J. Mol. Sci. 2017, 18, 2481; doi:10.3390/ijms18112481 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2017, 18, 2481 2 of 20
has been found in the spliceosome, where it is a required factor in the splicing of nuclear pre-mRNA [8].
This lectin also regulates cell cycle by modulating the activity of cyclins and their inhibitors, as well as
the phosphorylation status of retinoblastoma protein [9]. Of great interest for bone biology, intracellular
galectin-3 is a key regulator of the Wnt/β-catenin signaling pathway, both through its interaction with
β-catenin and because of its structural similarities with it [10]. Intracellular galectin-3 has also been
shown to promote cell proliferation [11,12] and favor survival by its anti-apoptotic activity, which is
related to its sequence homology and association with bcl-2 [11,13]. However, depending on the
cell type, galectin-3 can also promote apoptosis, as demonstrated by its involvement in T-cell and
neutrophil death [14].
Extracellular galectin-3 also participates in the control of cell cycle and division. Growth factors
immobilization into the galectin-3 lattice is, in fact, an additional mechanism for the regulation of cell
growth and differentiation [15]. In addition, cell surface galectin-3 has been shown to regulate cell
adhesion in opposite fashions, by both promoting homo- and heterotypic cell-to-cell interactions [16,17]
and down-regulating cell adhesion to the extracellular matrix component laminin, thus producing
an anti-adhesive effect [18,19].
Another important function of galectin-3 is the uptake and removal of advanced glycation
endproducts (AGEs) [20]. AGEs are a heterogeneous class of nonenzymatically glycated proteins,
lipids and nucleic acids, which accumulate in tissues during aging and, at a faster rate, in metabolic
disorders such as diabetes and obesity [20]. AGEs are toxic molecules inducing tissue injury by
direct and indirect mechanisms. In fact, they can exert detrimental direct physicochemical effects
by interacting with several molecules, thus inducing changes in enzymatic activity, ligand half-life,
binding, and immunogenicity [21]. Moreover, AGEs display indirect deleterious effects by binding to
several cell surface receptors, of which the most studied is the receptor for AGEs (RAGE), a 35-kDa
member of the immunoglobulin superfamily of receptors [22]. RAGE ligation is associated with cellular
oxidative stress [23] and activation of proinflammatory signaling pathways, eventually culminating in
tissue inflammation and fibrosis as well as in cell damage and death [20,24]. Noteworthy, galectin-3
and RAGE appear to exert opposite actions as AGE-receptors, with RAGE mediating the injurious
effects of AGEs and galectin-3 playing a protective role by favoring removal and degradation of these
toxic by-products [2,25].
Finally, galectin-3 plays an important role in the modulation of the immune/inflammatory
response, as evidenced by the numerous scientific reports showing a regulatory activity on both innate
and adaptive immunity [26]. Galectin-3 has been shown to exert both pro-inflammatory actions,
prevailing in an acute setting, and anti-inflammatory effects, particularly in chronic inflammatory
conditions, as recently reviewed [20]. In detail, well-established effects of galectin-3 on immune
cells include the stimulation of T-cell apoptosis [27], inhibition of T-cell growth and T-helper 1
differentiation [28], down-regulation of T-cell receptor-mediated T-cell activation [29], and induction
of alternative (M2) macrophage activation [30].
As much as concerning the bone, galectin-3 has been shown to be a marker of both chondrogenic
and osteogenic cell lineages. Aubin et al. were the first to report that chondroblasts and osteoblasts share
the expression of several molecules, including markers such as galectin-3 [31]. Later on, other groups
confirmed and extended this initial observation showing that galectin-3 is also found in osteoblasts and
osteocytes of the woven trabecular and cortical bone as well as in osteoclasts at the front of ossification and
mononuclear cells within bone marrow cavities [1]. In developing and mature bone, galectin-3 expression
seems to be restricted to the cytoplasm of chondrocytes and bone cells, although it is occasionally
detected in the nuclei of dense non-hypertrophic chondrocytes in the zone of calcification and of young
osteoblasts; conversely, no extracellular galectin-3 is detected in developing or mature bone tissue [1].
Noteworthy, Stock et al. demonstrated that the skeletal expression pattern of galectin-3 overlaps at many
sites with that of Runt-related transcription factor 2 (RUNX2), which is a key regulator of osteoblast
differentiation and chondrocyte maturation [32]. In summary, these early studies showed that galectin-3 is
widely distributed both in the developing and mature bone and that its expression is under control of the
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master regulator of bone growth RUNX2. These findings suggest that galectin-3 may be a key player in all
stages of bone biology, thus deserving to be thoroughly investigated as a potential target in bone disorders.
In this extensive review, we will present the results of studies that investigated the role of galectin-3 in
bone cell differentiation and function, in bone development and remodeling, and in the pathogenesis of
inflammatory bone diseases. We will also outline problems and aspects that have not been addressed yet,
or addressed only partially, which may represent relevant future research directions. Finally, the role of
galectin-3 in vascular osteogenesis, which was recently reported by us and other investigators [33–35],
will also be discussed. Figure 1 and Table 1 recapitulate the main findings discussed in this review, as well
as topics deserving further investigation in the future.
Figure 1. Galectin-3 osteogenic activities in bone and vascular tissue. Galectin-3 is considered
a marker of chondrogenic and osteogenic cell lineages and is up-regulated in conjunction with
other osteogenic markers during differentiation of bone cells. Consistent with a role in bone
physiology, galectin-3 deficiency affects endochondral ossification and bone remodeling. Galectin-3 is
also critical for maintaining proper extracellular matrix (ECM) structure and, possibly, bone competence.
Being also expressed by osteocytes, it is possible to hypothesize its participation in the regulation
of mechanosensory function of these cells and promotion of bone modeling and remodeling also
through this mechanism. Finally, galectin-3 activity is central for vascular smooth muscle cells (VSMCs)
transdifferentiation into an osteoblast-like phenotype and vascular osteogenesis. EVs = extracellular
vesicles; MSCs = mesenchymal stem cells.
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Table 1. Proven roles of galectin-3 in bone biology and supposed functions, to be investigated, in the
pathophysiology of bone metabolism.
Cell Proven To Be Investigated
Chondrocyte
cell marker and pro-survival factor [1,36]
regulator of cell-to-cell interaction with chondroclasts [37]
target and regulator of MMPs activity [38–40]
mechanisms underlying the regulation of
chondrocyte activity and survival
Osteoblast
RUNX2 target gene [32]
differentiation marker [41]
proper bone ECM structure by regulating collagen fibers synthesis [42]
protection against AGE mediated toxic effects by its AGE-receptor
scavenger activity [43–45]
mechanisms underlying the regulation of
osteoblast differentiationprotection from
age- and diabetes-related bone fragility
Osteocyte cell marker [1,41] mechanosensory function and promotion ofbone modelling and remodeling
MSC
increased osteoblastogenic differentiation capacity [46]
positive regulation of the master transcription factor RUNX2 [46]
stabilization and increase of β-catenin levels [46]
promotion of bone repair and homeostasis
through modulation of β-catenin
Osteoclast
differentiation marker [47]
mediator of cell matrix adhesion [48]
regulation of differentiation from progenitors and pro-survival factor [40]
downstream regulator of MMP-9 activity [40] and ECM degradation [37]
negative regulation of osteoclastogenesis [49,50]
opposite effects depending on intra- and
extracellular localization
MMPs = matrix metalloproteinases; RUNX2 = Runt-related transcription factor 2; ECM = extracellular matrix;
AGEs = advanced glycation endproducts.
2. Galectin-3 in Chondrocyte Differentiation and Endochondral Bone Formation
Endochondral ossification is an essential process by which most of the bones, particularly long
bones, of the mammalian skeletal system are formed during embryonic development. At variance
with intramembranous ossification, endochondral ossification involves formation of cartilage
elements (chondrocytes) from mesenchymal condensation, secretion of extracellular matrix by mature
chondrocytes and blood vessels invasion. During bone growth, cartilage anlage is progressively
replaced by bone tissue in a highly coordinate process, which is achieved also through a tight
balance between the rates of chondrocyte proliferation and apoptosis at the growth plate cartilage.
This is a specialized developmental tissue located at the metaphyseal level of long bones in which
chondrocytes are organized in three characteristic zones: proliferative, mature, and hypertrophic.
Chondrocytes are responsible for the synthesis of the major constituents of the matrix and the
enzymes that degrade cartilage matrix. Hence, their function is essential to regulate cartilage
synthesis and degradation, thereby coordinating the timing of vascular invasion and subsequent bone
deposition [51]. The elongation process takes place through a series of coordinated and complex events,
which include apoptosis of the chondrocytes in the terminal hypertrophic zone, partial degradation of
the calcified cartilage matrix, and bone matrix deposition by osteoblasts on the remaining cartilage
septa, which serve as a scaffold [52]. Failure in any of these events, including perturbations in
chondrocyte hypertrophy, would severely affect endochondral ossification and, consequently, normal
bone development [53].
Galectin-3 has been initially involved in the process of endochondral bone formation as
a regulator of chondrocyte survival. In fact, high levels of galectin-3 protein were demonstrated
in the differentiated chondrocytes of the metaphyseal plate cartilage of long bones of both fetal and
neonatal mice. The highest concentrations of galectin-3 were found in the cytoplasm of mature
and early hypertrophic chondrocytes [1]. At variance, very little expression was detected in the
late hypertrophic chondrocytes undergoing terminal maturation and cell death in the zone of
calcification, both at protein and mRNA levels. These findings are consistent with the anti-apoptotic
function of galectin-3 [11,13,54] and with the observation that galectin-3 null (Lgals3−/−) mice show
accelerated terminal differentiation and death of chondrocytes [1,36]. In addition to chondrocytes,
Colnot et al. reported high concentrations of galectin-3 also in the cytoplasm of osteoblasts, osteocytes,
and osteoclasts of trabecular and cortical bone, and in monocytes in the bone marrow cavity,
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thus suggesting a role for this lectin in the differentiation and/or activity of all the cell types present in
mature bone [1].
Subsequent comprehensive histological and ultrastructural analyses performed by the same group
identified a number of abnormalities in epiphyseal femurs and tibias of fetal Lgals3−/− mice, affecting
both chondrocytes of the proliferative, mature, and hypertrophic zones and the extracellular matrix
of the hypertrophic zone. The greatest abnormalities were detected at the chondrovascular junction,
where premature and increased cell death was associated with, and might account for, the increased
empty lacunae observed in mutant mice. Consistently, more numerous condensed chondrocytes
exhibiting characteristic signs of apoptosis were found in the late hypertrophic zone, indicating
that the rate of chondrocyte death was increased in Lgals3−/− mice. Taken together, these findings
suggest a role for galectin 3 as a regulator of chondrocyte survival and indicate that galectin 3 may
also participate in the coordination between chondrocyte death and metaphyseal vascularization.
At histological examination, the process of cartilage matrix mineralization appeared to be disturbed in
Lgals3−/− mice, both in terms of quantity and quality. However, despite these numerous abnormalities
of the metaphyseal growth plate cartilage, X-ray analysis conducted in adult Lgals3−/− mice did not
reveal significant macroscopic anatomical differences (i.e., final size) of long bones, indicating that the
initial defects are transient or, alternatively, have no impact on the process of bone elongation [42].
Another mechanism by which galectin-3 may regulate the process of endochondral ossification
emerged from studies investigating the cartilaginous bar of the mandibular arch (Meckel’s cartilage),
the middle portion of which is known to degrade via hypertrophy and death of chondrocytes and
cartilage resorption by chondroclasts/osteoclasts [37]. Sakakura et al. showed that galectin-3 levels
were especially higher in hypertrophic chondrocytes adjacent to chondroclasts. This observation
suggests that galectin-3 may also coordinate the resorption of calcified cartilage through cell-to-cell
interaction with chondroclasts, which are responsible for the synthesis and secretion of matrix
metalloproteinases (MMPs) involved in extracellular matrix degradation and in growth plate
angiogenesis [37]. Therefore, in addition to controlling chondrocyte cell cycling and survival,
evidence suggested that galectin-3 might participate in endochondral bone formation also through
regulation of MMPs activity, or vice versa [38,39]. According to this interpretation, deficiency of MMP-9
was shown to induce accumulation of galectin-3 in the expanded hypertrophic cartilage of developing
bone, which was associated with a decreased rate of chondrocyte apoptosis and accumulation of late
hypertrophic chondrocytes in the same zone [40]. This finding is consistent with the observation that
galectin-3 is an endogenous substrate of MMP-9, as indicated by in vitro experiments showing that
treatment of wild-type embryonic metatarsals with full-length galectin-3, but not MMP-9-cleaved
galectin-3, was able to reproduce the embryonic phenotype of Mmp-9−/− mice, characterized by
an expanded hypertrophic zone [40]. Altogether, these early studies indicated that galectin-3 and
MMP-9 represent two members of the same pathway implicated in the regulation of hypertrophic
chondrocyte clearance, degradation of extracellular matrix, and vascular invasion.
3. Galectin-3 in Bone Cell Differentiation and Function and Bone Homeostasis
3.1. Galectin-3 in Osteoblast Biology and Pathology
Osteoblasts are specialized, not terminally differentiated, mononuclear cells involved in secretion
and mineralization of the bone matrix, thus being responsible for new bone formation [55]. Osteoblasts
also control bone resorption through regulation of osteoclast activity, thus having a primary role in
modeling and preserving skeletal architecture [56]. Osteoblasts derive from the same mesenchymal
stem cell (MSC) precursors from which originate chondrocytes, adipocytes, and myoblasts [57],
depending on which transcription factor is expressed [55,57,58]. Among the most important
transcription factors recognized as specific and necessary to commit MSCs to the osteoblastic lineage
are RUNX2, also called core-binding factor subunit alpha-1, and osterix. Both these factors are essential
for osteoblastogenesis and, in their absence, no osteoblasts can be formed. Other important factors are
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activating transcription factor 4 and bone morphogenic proteins (BMPs), which provide important
signals that are essential for complete osteoblastogenic differentiation [57,58].
In culture, osteoblasts resemble the features of fibroblasts, except for the expression of RUNX2
and the bone-building protein osteocalcin (OCN). At the morphological level, osteoblasts differ from
fibroblasts for the unique, osteoblast-specific feature represented by the production of a mineralized
extracellular matrix [59]. In the bone microenvironment, as osteoblasts differentiate, they start to
secrete the organic portion of the bone matrix (osteoid) and to produce hydroxyapatite crystals that are
deposited into the organic matrix to form the bone’s mineralized structure. Ultimately, the osteoblast
becomes enclosed in the mineralized matrix and differentiate into mature osteocyte, a star-shaped
cell representing the most abundant cell type of mature bone [59]. This terminally differentiated bone
cell is involved in many aspects of bone biology, from the regulation of bone metabolism through
the expression of the negative regulator of bone mass sclerostin, to detection and transduction of
mechanical load into biological responses, thus adapting bone shape to daily mechanical forces [60].
However, the exact role of osteocytes in bone homeostasis is not completely defined, as reviewed
by Prideaux et al. [61].
The first report of a possible role for galectin-3 in osteoblast differentiation came from Aubin’s laboratory
in 1995. Using immunohistochemical and molecular approaches, this research group demonstrated
that osteoblasts and hypertrophic chondrocytes share the expression of galectin-3, in addition to
other markers such as alkaline phosphatase (ALP), OCN, bone sialoprotein (BSP), osteopontin (OPN),
and collagen type I. In addition, they observed that, in cultures of fetal rat calvaria, differentiation of
osteoprogenitor cells into mature osteoblasts forming bone nodules is preceded by a phase of intense
cell division, followed by loss of proliferative capacity and progressively increased expression of the
osteoblast markers mentioned above, including galectin-3 [31].
Subsequently, the same group confirmed and extended the initial observations by investigating
galectin-3 (both protein and mRNA) expression and regulation in several osteoblastic model systems,
including an in vitro model of osteogenesis and bone tissue in vivo [41]. The most striking evidence
in favor of a key role of galectin-3 in osteogenic differentiation was the observation that while
galectin-3 mRNA levels increased during long-term culture in rat calvaria cells, the mRNA expression
of the lectin fell down with time in culture of rat skin fibroblasts. Moreover, the amount of
galectin-3 mRNA and protein increased with time concomitant with the increase of osteoblast
differentiation markers and bone nodules formation. Finally, a role for galectin-3 in osteoblast
differentiation was also supported by the observations that (a) galectin-3 expression in differentiating
osteoblasts was modulated by two hormones known to affect osteogenesis, such as glucocorticoids
and 1,25-dihydroxyvitamin D; and (b) mature osteoblasts and osteocytes of calvaria bone showed
strong galectin-3 positivity, while faint staining was detected in immature osteogenic cells residing
in periosteum [41]. Although these early studies clearly demonstrated that galectin-3 is expressed by
osteoblast and that its levels increase during osteogenesis in parallel with the increased expression of
established osteogenic markers, the mechanisms by which galectin-3 may regulate differentiation and
activity of osteoblast or bone metabolism remains to be determined. Surprisingly, no further studies
have been conducted to pursue this aim. The only additional information on the role of galectin-3 in
osteoblast biology has come from a study investigating the molecular mechanisms through which the
mechanical load is converted into molecular signals in bone. Briefly, galectin-3 expression was found
to be up-regulated in the human osteoblastic HOBIT cell line exposed to extracellular nucleotides
concomitant to RUNX2 DNA-binding activity, thus suggesting that ATP and/or UTP released by
osteocytes in response to mechanical stimuli may account for the mechanosensory function of these
cells [62]. These data also confirmed indirectly the finding by Stock et al. that galectin-3 is a RUNX2
target gene in bone [32].
Though these studies suggest that galectin-3 is critical for osteoblast differentiation and function,
a recent report showed that exogenous recombinant galectin-3 inhibited terminal differentiation of
a human pre-osteoblast cell line [63]. This finding may suggest different, or even opposite effects of
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galectin-3 on osteoblastogenesis, depending on its intracellular or extracellular localization, as already
reported for other important regulatory functions in different cell types [20].
Regarding the possible involvement of galectin-3 in osteoblast and bone pathology, a couple
of studies investigated the AGE-receptor role of this lectin in the deleterious effects exerted by
AGEs on osteoblasts, as the possible molecular mechanism implicated in the pathogenesis of bone
remodeling disorders associated with aging and diabetes. These in vitro studies confirmed that
galectin-3, also known as AGE-receptor 3, and the best-characterized AGE receptor RAGE, are both
expressed in osteoblastic cell lines, including the MC3T3E1 mouse calvaria-derived osteoblasts,
and showed that AGEs are able to induce mRNA and protein levels of both AGE receptors [43,44].
In a previous study, the same investigators showed that exposure to AGEs elicits a biphasic response
in osteoblasts, with an early increase in cellular proliferation and expression of differentiation
markers, followed by induction of apoptosis and reduced differentiation in longer exposure to
AGEs [45]. Interestingly, the effect of AGE exposure on galectin-3 and RAGE up-regulation was also
time-dependent, with a prompt induction of galectin-3 expression and a delayed increase of RAGE
levels, which coincided with the opposite biological effects exerted by AGEs in osteoblasts [44].
Therefore, galectin-3 could be involved in the early effects of AGEs on osteoblasts, i.e., proliferation
and differentiation, while RAGE could be responsible for the long-term harmful effects of these
by-products, such as radical oxygen species (ROS)-induced apoptosis, activation of the Extracellular
Signal-regulated Kinase signal transduction pathway and inhibition of differentiation. These results
are also consistent with the opposite effects exerted by galectin-3 and RAGE in AGE-mediated disease
conditions, with the former playing a protective role through clearance of these toxic by-products
via endocytosis, and the second implicated in tissue injury [20,64]. Altogether, these findings point to
a possible role of the AGE/RAGE axis in the disorders of bone remodeling associated with aging and
diabetes, with galectin-3 as a putative protecting factor through scavenging of AGEs and promotion of
osteoblast differentiation and function.
3.2. Galectin-3 in Osteogenic Differentiation Capacity of Mesenchymal Stem Cells
MSCs are important for tissue and organ regeneration, including the bone. Consistently, it has
been reported that MSC commitment towards the osteogenic phenotype decreases with age,
an observation that might partly explain the impaired osteoblastogenesis observed in age-associated
osteoporosis [65,66]. However, though the number of mature osteoblasts is progressively decreasing with
advancing age, it was reported that the number of MSCs in mature bone remains constant throughout
life [67]. This suggests that the age-dependent gradual reduction of ostoblastogenesis might be the
consequence of a loss of function of MSCs or, alternatively, a perturbation of the environmental signals
involved in the osteogenic commitment of MSCs [46], such as growth hormone [68] and estrogens [69].
Interestingly, it has been recently demonstrated that exposure to the systemic environment of
young, but not elderly individuals favors MSC functionality and bone repair through modulation
of β-catenin [70]. Therefore, attention has recently focused on the search for secreted circulating
factors favoring stem and progenitor cell function. In this endeavor, special consideration has been
paid to extracellular vesicles (EVs), which are small vesicles carrying proteins, mRNAs, and other
molecules through the circulation [71]. EVs are released by most of the body’s cells [72] and their cargo
is delivered to specific recipient cells [73]. Recently, Weilner et al. demonstrated that EVs isolated from
young donors were more effective in inducing osteoblastogenesis in vitro compared to vesicles derived
from elderly individuals. Interestingly, this osteoblastogenic donor age-dependent effect mediated
by EVs was directly associated with galectin-3 content, which was higher in the EVs from young
individuals [46]. These data indicated that galectin-3 not only plays an important role in the late stage of
osteoblast differentiation and maturation, as previously shown [32,41], but also enhances the osteogenic
differentiation capacity of MSCs favoring β-catenin activity. Mechanistically, galectin-3’s serine-96
phosphorylation site was found to compete for the glycogen synthase kinase-3β phosphorylation site
on β-catenin, which represents a crucial step in the degradation of this transcriptional coactivator [46].
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Finally, Weilner et al. also showed that even a moderate increase of galectin-3 expression induced ALP
and RUNX2 expression in MSCs, thus suggesting that galectin-3 is not only a target gene, but it is also
a positive regulator of the master osteogenic regulator RUNX2 [46].
In conclusion, these data confirm and expand previous reports on the importance of galectin-3
in osteoblast differentiation and propose an additional role for this lectin in bone remodeling,
demonstrating that MSCs osteogenic differentiation is dependent on galectin-3 levels in circulating
EVs. Therefore, it is tempting to speculate that the age-dependent reduction of galectin-3 EVs content
might contribute to the reduction of bone formation, development of osteoporosis, and increased
facture risk in the elderly [46].
3.3. Galectin-3 in Osteoclast Biology
Osteoclasts are large multinucleated cells responsible for bone resorption by degrading
mineralized matrix. This cell type is critical for normal bone remodeling and is responsible for bone loss
in pathologic conditions by increasing resorptive activity. Osteoclasts are terminally differentiated cells
from immature hematopoietic monocyte/macrophage progenitors, a process regulated by multiple
factors, including receptor activator of NF-κB ligand (RANKL), its decoy receptor osteoprotogerin
(OPG), and macrophage colony-stimulating factor released by osteoblasts [74]. Once recruited to
the bone, osteoclast precursors crawl to the resorption site, fuse with other precursors, and attach to
the bone surface. Attachment to the bone matrix is a critical event in osteoclast activation, leading
to osteoclast actin cytoskeletal reorganization and formation of sealing zones, which are composed
of specialized integrin-mediated adhesive structures called podosomes [75]. It is well-known that
protein-bound carbohydrates on the outer cell surface contribute to specific cell-cell and cell-matrix
recognition [47]. Therefore, receptors for carbohydrates on osteoclasts and their precursors likely
have a pivotal role in mediating cell-matrix interactions and, possibly, in regulating other related
activities, such as migration, differentiation, and bone resorption. Since galectin-3 has been recognized
as an abundant laminin-binding protein of macrophages [76], which share with osteoclasts a common
lineage, its possible function in osteoclast activity has attracted some attention.
Galectin-3 expression by osteoclasts was originally described by Niida et al. in 1994. They reported
that mouse tartrate-resistant acid phosphatase (TRAP)-positive mononuclear precursors (pre-osteoclasts)
and mature osteoclasts are positive for galectin-3, but negative for the specific murine macrophage marker
F4/80. In more detail, galectin-3 was detected in the cytoplasm and nucleus of pre-osteoclasts, as well
as on their plasma membrane, suggesting a potential role of this lectin in cell-matrix adhesion during
differentiation [48]. These initial findings were confirmed by Colnot et al. who reported that mature
resorbing cells present an immunostaining for galectin-3 in their cytoplasm, including the multinucleated
osteoclasts actively involved in resorbing the calcified cartilage core in the metaphysis and those present in
the trabecular bone of neonatal mice [1]. They also noted positive staining for galectin-3 in mononuclear
cells inside the bone marrow cavity [1]. Therefore, from these initial reports, it appeared that galectin-3
is expressed by bone osteoclasts and by their monocyte progenitors. Since galectin-3 is a well-known
macrophage marker and is essential for phagocytosis [77], this lectin can be considered as a marker of
the entire monocyte-macrophage-osteoclast cell lineage and it can be assumed that it is critical for some
important osteoclast function. A few years later, Gorski et al. found two new alternatively spliced sequences
of galectin-3 expressed by chicken osteoclasts [47]. Interestingly, galectin-3 expression was found to rise
dramatically in bone marrow cells after 5 days of in vitro culture in an osteoclast differentiation media,
suggesting a role for this lectin in the acquisition of the main phenotypic characteristics of osteoclasts,
such as displaying TRAP activity, multinuclearity, and owning the capacity to resorb bone [47].
The role of galectin-3 in regulating osteoclast differentiation and activity was also investigated
by Ortega et al. These Authors found that, besides playing a role in hypertrophic chondrocyte
differentiation, galectin-3 also regulates osteoclast recruitment to the primary ossification center during
endochondral bone formation, as well as differentiation of mononuclear osteoclast progenitors and
osteoclasts survival at the chondro-osseous junction [40]. Consistent with a key role for endogenous
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galectin-3 in the biology of cells of the osteoclast lineage, Ortega et al. reported that mice null
for MMP-9, the prominent MMP for cleavage of the N-terminal domain of galectin-3, displayed
an increased number of galectin-3 positive cells, in parallel with an increase of TRAP immunostaining
at the front of ossification. They also confirmed these data in an embryonic metatarsal culture system,
observing that an excess of exogenous recombinant galectin-3, besides from increasing the number of
TRAP-positive cells at the front of ossification, also interfered with recruitment of osteoclast precursors.
Altogether, these findings suggest that aberrant persistence of higher levels of extracellular galectin-3,
both exogenous or as a consequence of reduced cleavage by MMP-9, may induce abnormal osteoclast
survival and, eventually, excessive bone remodeling [40].
3.4. Galectin-3 in Bone Remodeling
Bone remodeling is a lifelong process by which bone is renewed to maintain bone mass.
Bone remodeling involves finely orchestrated cellular and molecular events and is commonly viewed as
a two-step process carried on by bone cells: it involves old bone resorption by osteoclasts followed by
new bone formation by osteoblasts [78]. These two arms of bone remodeling must occur in a balanced
and coordinated manner in order to maintain bone mass and shape largely unchanged throughout
adult life. Therefore, both increased bone resorption by osteoclasts or reduced bone formation by
osteoblasts can lead to bone loss [79,80]. Indeed, bone metabolism is more complex than a two-step
process, and there is still a lot to be learned about cellular and molecular mechanisms involved in
remodeling. Particularly, unbalance between bone resorption and bone formation leading to reduced
bone mass might be the result of multifaceted events affecting simultaneously osteoblasts and osteoclasts.
Unfortunately, our knowledge of the molecular regulators that modulate differentiation and activity of
osteoclasts and osteoblasts is still insufficient [81], thus hampering the identification of new therapeutic
strategies to reduce the health burden and costs related to osteoporotic fractures, which are expected to
increase in the future [82].
Although galectin-3 has been found to play a critical role in the differentiation and/or function
of chondrocytes, osteoblasts osteocytes and osteoclasts [1,31,32,36–42,44,45,47,48,62,63], and even
in favoring MSC osteogenic differentiation [46], so far, only one study has addressed the role of
this lectin in bone homeostasis [49]. Simon et al. demonstrated that Lgals3−/− mice exhibited
altered bone homeostasis, as attested by histomorphometric analysis and micro-computer tomography
measurements revealing a decreased trabecular bone volume in 12-week-old male Lgals3−/− mice
compared to wild-type littermates. Surprisingly, however, the role of galectin-3 in osteoblast
differentiation was not investigated in this study, nor it was evaluated the effect of galectin-3 deficiency
on the ability of osteoblast to form calcified nodules in vitro and new bone (bone formation rate)
in vivo. However, at this age, the number of osteoblasts in bones of Lgals3−/− mice was not different
compared with wild-type mice [49]. At variance, bones of Lgals3−/− mice exhibited an increased
number of osteoclasts in the absence of changed RANKL/OPG ratio, a finding suggesting a direct
inhibitory effect of galectin-3 on osteoclastogenesis. Consistent with this hypothesis, but at variance
with previous studies indicating a positive effect of galectin-3 on osteoclast differentiation and
maturation [40,47,48], bone marrow cells from Lgals3−/− mice displayed an increased osteoclastogenic
ability in ex vivo differentiation assays combined with a higher resorption activity. From a mechanistic
perspective, molecular analysis revealed higher mRNA levels of the tumor necrosis factor receptor
associated factor 6, a critical factor in RANKL signaling and terminal differentiation of osteoclast
progenitors. Also in contrast to previous studies [40,47,48], exogenous galectin-3 added to wild-type
murine or human osteoclasts was able to inhibit osteoclast differentiation. Moreover, co-culture
assays of wild-type osteoclasts with galectin-3 deficient osteoblasts favored osteoclast maturation
(size) and number [49]. Based on these findings, Simon et al. concluded that galectin-3 may be
part of a molecular mechanisms through which osteoblasts control osteoclastogenesis at sites of
mineralization. However, further research is needed to characterize the bone phenotype of Lgals3−/−
mice during growth and aging, to clarify the role of endogenous galectin-3 in osteoclast differentiation
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and function and, importantly, to elucidate the role of this lectin in regulating osteoblast activity in vivo.
Regarding this last topic, previous reports described irregular structure of the extracellular matrix in
bones from Lgals3−/− mice, which displayed loss and reduced length of collagen fibers compared with
wild-type animals [42]. Interestingly, these structural abnormalities of the bone matrix may account for
the empirical observation of bone femur fragility of these mice [83]. Altogether, these findings suggest
a critical role for galectin-3 also in the molecular architecture of the mineralized matrix, in maintaining
bone quality, and in the optimization of bone strength. However, these assumptions were not confirmed
by Simon et al. who reported unchanged mechanical stiffness of femurs in Lgals3−/− mice compared
with wild-type mice, as assessed by four-point bending test [49].
4. Galectin-3 in Inflammatory Bone and Joint Disorders
Arthritis is an inflammatory disorder of the joints. The two most common form of arthritis
are rheumatoid arthritis (RA) and osteoarthritis (OA). They share common symptoms, such as pain,
swelling, and stiffness of the joints, leading to disability. However, these two inflammatory joint
disorders differ in etiological factors and pathogenesis [84]. In fact, while RA is an autoimmune
disease characterized by autoantibody production, no specific causes have been identified for OA,
which is generally considered a degenerative disease, being the result of “wear and tear” of the joints.
Moreover, though chronic inflammation is a feature of both joint diseases, synovitis is a primary event in
RA [85], whereas inflammation of the synovial membrane is a late event in OA, secondary to cartilage
destruction and erosion [86]. In the clinical setting, synovial levels of galectin-3 are elevated in both RA
and OA [87–89], though to a greater extent in the former [87,88]. However, it is unclear how galectin-3
is involved in the pathogenesis and progression of RA and OA, also because of the contradictory results
obtained so far from diverse studies on different experimental models of these disorders. For the purpose of
the review, we will only discuss in detail the most important experimental studies on the role of galectin-3
in OA and RA and the reader is referred to a recent review on the subject [84].
The role of galectin-3 in articular tissues and OA has been recently investigated using human OA
chondrocytes and mice with OA induced by injection of mono-iodoacetate (MIA). Besides confirming
the critical role of galectin-3 in chondrocyte survival [1,32,36,37,40,42], this study demonstrated that
intracellular galectin-3 preserves cartilage structures, as evidenced by the finding of an accelerated
age-dependent cartilage erosion in Lgals3−/− mice. In fact, cartilage score of 4-month-old Lgals3−/−
mice was the same as in coeval wild-type mice injected with MIA, which also displayed cartilage lesions
similar to those found in Lgals3−/− mice. Moreover, the decrease of subchondral bone surface induced
by MIA in wild-type mice was further accentuated in Lgals3−/− mice, suggesting that galectin-3
may be essential for remodeling of the subchondral bone. Thus, this study showed a protective role
of intracellular galectin-3 in OA and suggested that it is essential for cartilage homeostasis during
ageing as its absence induced OA-like lesions. In addition, lack of galectin-3 during the OA process
accelerated tissue injury in the joint [90].
In RA, the chronic inflammation of the synovial lining is accompanied by severe destruction
of articular cartilage and bone erosion [85], which is mainly mediated by osteoclasts [50,91].
The prominent role of osteoclasts was also demonstrated using mice deficient in RANKL, an essential
factor for osteoclast differentiation, showing that they were protected from articular bone loss in
a serum transfer model of arthritis [92]. However, to make things more complicated, osteoblast
function and new bone formation may also be negatively affected at sites of inflammation and
erosion, thereby contributing to the net loss of bone [93]. Li et al. investigated the involvement
of galectin-3 in bone destruction around the ankle joints in rats with adjuvant-induced arthritis
(AA), which is considered an experimental model of human RA [94]. In this study, galectin-3 was
shown to be abundantly expressed by macrophages and granulocytes accumulated in the areas of
severe bone destruction in rats with AA, but only weakly by osteoclasts. This observation indicated
an association between galectin-3 expression and incidence of arthritis. Moreover, galectin-3 injection
in the affected joints was able to suppress bone destruction and reduce osteoclast recruitment,
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suggesting a protective role of the lectin. In vitro experiments confirmed the in vivo findings,
demonstrating that exogenous recombinant galectin-3 was able to inhibit both formation of osteoclasts
and dentine resorption by mature osteoclasts. Therefore, this study demonstrated a protective role
of galectin-3 in AA-induced bone destruction and suggested that the protective effect of galectin-3
may be mediated by its negative regulation of osteoclastogenesis [94]. However, this conclusion is in
contrast with previous data suggesting a critical role for this lectin in osteoclast differentiation and
function [40,47]. Moreover, from these data, it cannot be ruled-out a protective role mediated by the
anti-inflammatory, pro-resolution effect of galectin-3 [20,27–30,95]. Likewise, it cannot be excluded the
possibility that the pro-osteogenic properties of galectin-3 may have contributed to protection from
net bone loss. It must also be noticed that a recent work has put into question the results obtained by
Li et al., proving that Lgals3−/− mice are protected from joint injury associated with AA [96].
To our knowledge, the only study on the role of galectin-3 in a specific, non-tumoral, bone pathology
was performed by Wehrhan et al. who investigated the molecular mechanisms involved in the
pathogenesis of bisphosphonate-associated osteonecrosis of the jaw (BRONJ). BRONJ is an oral disorder
characterized by an impairment in hard- and soft tissue repair. It is characterized by bisphosphonate-related
impairment of oral tissues remodeling, involving bone cells, fibroblasts, and keratinocytes [97]. In addition,
Reid et al. reported that BRONJ was associated to increased osteogenic differentiation of mucoperiosteal
progenitors, anergy of the affected tissues, and increased galectin-3 expression in the periosteum and
fibrous tissue stroma cells [97], thereby differing from osteoradionecrosis-related mucoperiosteal tissue,
which was characterized by local inflammation and significantly less galectin-3 staining [98]. On the
basis of the evidences indicating that galectin-3 is involved in the differentiation of osteoblasts and
chondroblasts [1,31,32,36,37,40–42,44,45] and mediates inhibition of intraoral inflammation [97,99],
the Authors concluded that the higher levels of galectin-3 might be involved in both the increased
osteogenic differentiation of the mucoperiosteal precursors and the inflammatory anergy observed in
BRONJ-affected soft tissues.
5. Galectin-3 in Vascular Osteogenesis
A large body of evidence indicates that vascular calcification is an unfavorable event in the
natural history of the atherosclerotic disease. Consistently, coronary calcium score independently
predicts cardiovascular morbidity and mortality, thus directly linking the amount of calcium in the
vessel wall with unfavorable outcomes [100,101]. However, recent findings suggest that vascular
calcification may either promote plaque progression and vulnerability or favor plaque stability,
depending on the elemental composition [102] and pattern [33] of calcium deposition within the
vessel wall. For instance, intravascular ultrasound studies indicate that spotty, granular and less dense
calcification (commonly referred to as “microcalcification”) within a fibro-atheromatous plaque is the
main pattern of calcium deposition in patients with acute myocardial infarction, whereas extensive
dense calcification (commonly referred to as “macrocalcification”) prevails in subjects with stable
angina pectoris [103–105]. However, despite the increasing body of evidence supporting the dual role
of calcification in plaque stability and its clinical implications, little is known about the biological
mechanisms that favor one type of vascular calcification over the other.
Though previously considered as a passive degenerative phenomenon [106], vascular calcification
is now proven to be an active, tightly regulated process, similar to bone mineralization, activating
an osteogenic gene regulatory program and involving various bone-related proteins. Many mechanisms
have been proposed to explain the phenomenon of ectopic calcification within the vessel wall, including
the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs) [107]. These specialized
contracting cells are an important structural component of the artery wall, playing a key role in
maintaining vascular tone and participating to various important functions, such as the regulation of
blood pressure. VSMCs also play a key role in different pathological processes affecting the vasculature,
including the pathobiology of vascular calcification. The process of VSMCs transdifferentiation towards
osteochondrogenic precursors is a process characterized by progressive expression of the osteochondrogenic
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markers OCN, ALP, and OPN, associated with the expression of the osteochondrogenic transcription factor
RUNX2. This process is also accompanied by phenotypic transition of VSMCs, attested by progressive
reduction of expression of α smooth muscle actin, the main smooth muscle lineage marker, and loss of the
contractile phenotype [108,109]. Several pro-inflammatory and pro-osteogenic stimuli have been shown to
promote vascular calcification in the setting of atherosclerosis, including ROS [110], AGEs [111], advanced
lipoxidation end-products [112], calgranulins [113], BMPs [114], and OPG [115]. However, most of the
in vitro and in vivo studies performed to investigate the role of these stimuli in atherosclerotic vascular
calcification have only assessed the quantitative aspect of the phenomenon, irrespective of the type of
calcification process in which they are involved.
Some insight into the mechanism regulating the pattern of calcification in the process of atherogenesis
has been recently provided [33]. Interestingly, this mechanism involves galectin-3 and RAGE, which were
previously shown to modulate in opposite ways osteoblast differentiation and function in the presence
of AGEs. In fact, while galectin-3 was shown to favor osteoblast differentiation, RAGE was found
to be responsible for the detrimental effects of AGEs on osteoblasts, such as apoptosis and reduced
differentiation [44]. Consistent with a pro-osteogenic effect of galectin-3 also in VSMC transdifferentiation,
the increased expression of osteogenic markers induced by incubation in osteogenic medium was
accompanied by a parallel increase in galectin-3 expression, in accordance with what was observed in
differentiating osteoblasts [31]. In addition, galectin-3 deficiency was associated with defective osteogenic
transdifferentiation of VSMCs, as attested by reduced expression of the osteogenic transcription factor
RUNX2 and the bone cell marker ALP, enhanced apoptosis, reduced proliferation, and disorganized
mineralization [33]. Lgals3−/− VSMCs cells also showed decreased activation of Wnt/β-catenin signaling,
which is in agreement with galectin-3’s ability to stabilize and increase β-catenin levels in MSCs
differentiating towards the osteogenic lineage [46]. Noteworthy, the reduced ability of Lgals3−/− VSMCs
to acquire an osteogenic phenotype was also associated with RAGE up-regulation, and was exacerbated
by treatment with AGEs, once again in keeping with previous data on osteoblast differentiation [44].
In vivo analysis of carotid plaques from patients undergoing carotid endarterectomy supported the
hypothesis that galectin-3 and RAGE regulate in opposite ways the pattern of calcification, with RAGE
expression observed in plaque regions with diffuse microcalcification and galectin-3 being mainly expressed
by VSMCs in regions adjacent to extended and dense macrocalcification, where it colocalized with the
osteogenic marker ALP [33].
Altogether, these data demonstrated that galectin-3 is essential for full transdifferentiation of
VSMCs into an osteoblast-like phenotype via modulation of the Wnt/β-catenin pathway. They also
provided evidence for a role of galectin-3 and RAGE in determining the pattern of calcification in
atherosclerotic lesions. Noteworthy, the roles played by galectin-3 and RAGE in regulating VSMC
transdifferentiation and vascular calcification recapitulate the effects they have at the skeletal level.
In fact, galectin-3 was shown to regulate chondroblast/osteoblast differentiation/function and bone
development [1,31,41]. Conversely, RAGE was shown to be essential for osteoclast maturation and
function in skeletal tissue both in vivo and in vitro [116].
Finally, an ancillary observation is that a large body of literature indicates a role of galectin-3
as a prognostic marker in cardiovascular disease. In particular, elevated levels of circulating
galectin-3 have been found to be associated with higher risk of death in heart failure patients [117].
Moreover, some experimental evidence suggests an active role of this lectin in cardiac remodeling
and atherosclerosis, mainly through its recognized fibrogenic properties [20,117]. However, given the
important role played by vascular calcification in atherosclerosis and cardiovascular disease, and that of
galectin-3 in VSMCs osteogenic transdifferentiation, it cannot be rule out the possibility that circulating
galectin-3 might affect cardiovascular disease also through its osteogenic properties.
6. Conclusions
Most of the study conducted to investigate the role of galectin-3 in the biology of bone and its
cells date back to the late 90s of last century and the beginning of 2000s. Although they produced
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convincing evidence about the involvement of this lectin in multiple biologic processes of the bone,
such as differentiation and activity of all major bone cells, they were not followed by an in-depth
analysis of the role of galectin-3 in the bone physiology and pathology. Only recently, the skeleton of
Lgals3−/− mice has been analyzed and results demonstrated that, in fact, adult (3-month-old) mice
have a bone phenotype, characterized by reduced trabecular bone compared with wild-type mice [49].
However, the analysis of the mechanisms underlying the structural abnormalities only investigated the
resorption arm of the bone remodeling process, leaving completely unexplored the bone deposition arm
and the cells responsible for bone formation. Since, galectin-3 has been shown to have a critical role for
chondroblast and osteoblast differentiation and activity [1,31,32,36,37,40–42,44,45], an in-depth analysis
of these cells and their function in Lgals3−/− mice is necessary to understand the net effect of this lectin
on bone homeostasis. It would also be desirable to extend the analysis to the skeleton of younger and
older Lgals3−/− to get information on the role of this lectin in growth and age-dependent changes of
the bony structure. These analyses could provide valuable information possibly helping in identifying
galectin-3 as potential therapeutic target in some bone pathologies, primarily senile osteoporosis.
This concept is strengthened by the evidence that, in addition to its role in osteogenesis, (a) galectin-3
is able to stimulate osteogenic differentiation of MSCs [46]; (b) in osteoblast lineage cells [43–45], it acts
as a receptor capable of degrading AGEs, which have been implicated in age-dependent [118] and
diabetes-associated [119] bone fragility; and (c) it may favor resolution of chronic inflammation [20],
also in the bone tissue [20,97–99].
Finally, the osteogenic properties of galectin-3 deserve to also be investigated in the process
of ectopic calcification, primarily vascular osteogenesis. The possibility of modifying the amount
and especially the type of calcification in the atherosclerotic plaque by modulating the expression
of galectin-3 could be very useful in stabilizing the atherosclerotic lesions, thus reducing the risk of
fatal events.
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